HB-1734

N/A

Report date: 2023/11/06 17:29:21

Base Information

Drug NameHB-1734
Drug Alias NameHB1734HB-1734
ClassificationBiologics
Mechanisms of ActionInterleukin-36 receptor modulatorsInterleukin 17A modulators
TargetsInterleukin-36 receptorInterleukin 17A
Therapy Area/IndicationsScleroderma, SystemicIdiopathic Pulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Huaota Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Huaota Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicIdiopathic Pulmonary Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A